IQVIA Introduces Orchestrated Customer Engagement to European Market at eyeforpharma Barcelona

BARCELONA, SPAIN and LONDON, UK, 13th March 2018 – Today at the eyeforpharma congress, IQVIA (NYSE:IQV) introduces its new Orchestrated Customer Engagement (OCE) solution to the European market. OCE is an innovative technology that supports organisations across the EMEA region to drive a new commercial model of orchestration, uniquely adapted for the life sciences industry, enabling them to collaborate more effectively.

Built on best-in-class technologies, OCE manages the complexity of tracking multiple interactions and markets to ensure value for the customer. OCE provides native integration across a “platform of platforms,” seamlessly connecting those in operations, IT, sales, marketing and other functions; enabling the sharing of data and more accurate data reporting; and allowing for easier and quicker implementation.

Early adopters of the OCE solution include Merck and Pierre Fabre. “Orchestrating our company’s engagement with our customers by leveraging new technologies is an important part of our commercial strategy,” said Chetak Buaria, Global Head of Commercial Excellence (Biopharma), Merck KGaA, Darmstadt, Germany. “For this reason, we are delighted to co-operate with IQVIA on OCE. This cooperation will give us the ability to influence the solution roadmap and experiment new customer engagement models early on.” OCE leverages IQVIA’s Ada™, artificial intelligence that gives users recommendations for next-best actions; Apollo™, an intuitive user interface; and Lexi™, an application program interface (API) layer to connect all applications and data using common language. Life sciences companies are able to implement OCE with IQVIA or with other providers certified within the ecosystem.

IQVIA President, North Europe, Middle East, South Asia and Africa, Alistair Grenfell, said, “Success in the life sciences sector is built on trust and meaningful interaction between companies and their medical professional stakeholders. Key to building that trust is the ability to organise interactions in a way that meets the personalised needs of the individual stakeholder. The OCE solution significantly enhances a company’s ability to do this, by seamlessly integrating the work of different disciplines and providing a genuine 360 view of customer engagement. It also offers significant efficiency and potential cost-savings. At IQVIA we believe OCE is the future of customer engagement and we are proud to introduce this next-generation system to Europe.”
For more information on Orchestrated Customer Engagement (OCE), please visit Exhibit 37-42 at the eyeforpharma Barcelona conference, or the IQVIA website.
Contact us at

IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services focused on using data and science to help healthcare clients find better solutions for their patients. Formed through the merger of IMS Health and Quintiles, IQVIA offers a broad range of solutions that harness advances in healthcare information, technology, analytics and human ingenuity to drive healthcare forward. IQVIA enables companies to rethink approaches to clinical development and commercialization, innovate with confidence as well as accelerate meaningful healthcare outcomes. IQVIA has approximately 55,000 employees in more than 100 countries, all committed to making the potential of human data science a reality. IQVIA’s approach to human data science is powered by the IQVIA CORE™, driving unique actionable insights at the intersection of big data, transformative technology and analytics with extensive domain expertise.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing the information that helps their customers drive human health outcomes forward. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit